These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28622736)

  • 1. Vaxchora: A Single-Dose Oral Cholera Vaccine.
    Cabrera A; Lepage JE; Sullivan KM; Seed SM
    Ann Pharmacother; 2017 Jul; 51(7):584-589. PubMed ID: 28622736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
    Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
    Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
    Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traoré A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
    Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on CVD 103-HgR single-dose, live oral cholera vaccine.
    McCarty J; Bedell L; De Lame PA; Cassie D; Lock M; Bennett S; Haney D
    Expert Rev Vaccines; 2022 Jan; 21(1):9-23. PubMed ID: 34775892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Kaper JB; Levine MM
    J Infect Dis; 1992 Oct; 166(4):837-41. PubMed ID: 1527420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine.
    Jackson SS; Chen WH
    Future Microbiol; 2015; 10(8):1271-81. PubMed ID: 26228388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022.
    Collins JP; Ryan ET; Wong KK; Daley MF; Ratner AJ; Appiah GD; Sanchez PJ; Gutelius BJ
    MMWR Recomm Rep; 2022 Sep; 71(2):1-8. PubMed ID: 36173766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
    McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
    Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR.
    Herzog C
    Travel Med Infect Dis; 2016; 14(4):373-7. PubMed ID: 27425792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholera vaccines.
    Ryan ET; Calderwood SB
    Clin Infect Dis; 2000 Aug; 31(2):561-5. PubMed ID: 10987721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.
    Levine MM; Kaper JB; Herrington D; Ketley J; Losonsky G; Tacket CO; Tall B; Cryz S
    Lancet; 1988 Aug; 2(8609):467-70. PubMed ID: 2900401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.
    Chen WH; Greenberg RN; Pasetti MF; Livio S; Lock M; Gurwith M; Levine MM
    Clin Vaccine Immunol; 2014 Jan; 21(1):66-73. PubMed ID: 24173028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
    Lagos R; San Martin O; Wasserman SS; Prado V; Losonsky GA; Bustamante C; Levine MM
    Pediatr Infect Dis J; 1999 Jul; 18(7):624-30. PubMed ID: 10440439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area.
    Richie EE; Punjabi NH; Sidharta YY; Peetosutan KK; Sukandar MM; Wasserman SS; Lesmana MM; Wangsasaputra FF; Pandam SS; Levine MM; O'Hanley PP; Cryz SJ; Simanjuntak CH
    Vaccine; 2000 May; 18(22):2399-410. PubMed ID: 10738097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.